Ronald Burch

Nerve-stim startup Sanguistat shuffles its deck

By GREGORY ZELLER // A Connecticut-based biotech spun out of the Feinstein Institute for Medical Research has assembled a powerful collection of advisors and directors, including corporate heavyweights and recognized global leaders in the burgeoning field of biolelectronic medicine. Sanguistat Inc., a 2016 clinical-stage medical-device startup, has named Feinstein Institute President and CEO Kevin Tracey as chairman of its Scientific Advisory Board, a role that will leverage the pioneer’s decades of groundbreaking bioelectronics research. The…


Nerves of steel: Sanguistat stimulator steps up

By GREGORY ZELLER // The world’s leading cause of maternal deaths is the target of new clinical trials for a trailblazing bioelectronic medical device. The Neural Tourniquet, an electronic nerve-stimulation technology licensed to Sanguistat Inc. by the Feinstein Institute for Medical Research, is seeing action against postpartum hemorrhage in new clinical trials underway at Feinstein, the research arm of the Northwell Health system. Sanguistat, a 2016 clinical-stage medical device spinoff founded by Feinstein Vice President…


Feinstein launching Neural Tourniquet as newco

By GREGORY ZELLER // Meet Sanguistat, the corporate face of the latest technology spinning out of Northwell Health’s Feinstein Institute for Medical Research. For now, Sanguistat is not an Inc. or LLC. But it does have co-founders – Feinstein vice president Christopher Czura, who will be the new company’s chief scientific officer, and Jared Huston, a medical doctor and Feinstein researcher who will serve as chief medical officer. Czura and Huston are also listed as…